CBD and CBG may reduce fatty liver diseaseResearch

According to Israeli researchers, two compounds derived from cannabis could offer a solution to what is commonly known as “fatty liver disease.”

Non-alcoholic steatohepatitis (NASH), a liver disease associated with metabolic dysfunction, is the most common liver condition in the world, affecting nearly one in three adults.

And yet, “there is no medication for this disease,” Professor Yossi Tam of the School of Pharmacy at the Hebrew University of Jerusalem explained to The Times of Israel over the phone.

Tam, 51, who is also director of the university’s Multidisciplinary Cannabinoid Research Center, led a groundbreaking study showing that cannabidiol (CBD) and cannabigerol (CBG)—which are non-psychoactive and do not cause any euphoric effects—can improve

euphoric, can improve liver health by altering its energy management and detoxification processes.

The peer-reviewed mouse studies were published last Friday in *The British Journal of Pharmacology*. They reveal what Tam describes as the liver’s mechanism for managing its energy and detoxification—processes that were previously poorly understood.

Also contributing to this study were lead author and PhD student Radka Kočvarová, Dr. Liad Hinden from Tam’s lab, and, Dr. Liad Hinden from Tam’s laboratory, along with researchers from the Technion, Israel Institute of Technology.

“Given that one-third—if not more—of Western adults are at risk of developing this disorder, which accompanies the obesity epidemic, [this study] is of great importance to public health,” explains Dr. Ethan Russo, founder and CEO of CReDO Science, a research, development, and education company specializing in cannabis.

TO CONTINUE READING: The Times of Israel